Evidence map›Paper›PMID 20530700›Full record

ReviewClinical cancer research : an official journal of the American Association for Cancer Research2010

The difficulty of targeting cancer stem cell niches.

Mark A LaBarge

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed.

  1. Targeted Cancer Stem Cell Therapeutics: An Update.Current topics in medicinal chemistry · 2025
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Two Faces of Autophagy in the Struggle against Cancer.International journal of molecular sciences · 2021
    Review
  9. Article
  10. P2X7 receptor: a critical regulator and potential target for breast cancer.Journal of molecular medicine (Berlin, Germany) · 2021
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Energy metabolism in cancer stem cells.World journal of stem cells · 2020
    Review
  16. Review
  17. Review
  18. A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer.Journal of experimental & clinical cancer research : CR · 2019
    Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mark A LaBargeLife Science Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA. MALabarge@lbl.gov

Funding

The role of microenvironment in aging-related phenotypes of breastR00AG033176 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI LABARGE, MARK A · 2010 to 2012
$703k
The role of microenvironment in aging-related phenotypes of breastK99AG033176 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI LABARGE, MARK A · 2009 to 2009
$77k
NIA NIH HHS K99 AG033176NIA NIH HHS K99AG033176NIA NIH HHS R00 AG033176
6 · The paper itself

Abstract

Normal stem cell niches typically are identified by their distinctive anatomical features and by association with tissue-specific stem cells. Identifying cancer stem cell (CSC) niches presents a special problem because there are few if any common anatomical features among tumors, and the physical phenotypes that reportedly describe the CSCs as entities may be subject to the host's microenvironment, sex, and tumor stage. Irrespective of a niche's location, the occupant's phenotype, or the precise molecular composition, all niches must do basically the same thing: maintain the activities in a stem cell that define it as such. Therefore, a potentially successful strategy, both for elaborating a molecular and cellular portrait of a CSC niche, and for therapeutically targeting them, is to identify components in the tumor microenvironment that are required for maintaining the functions of self-renewal, differentiation, and quiescence in the face of cytotoxic therapeutic regimens.

Indexed as

Drug Delivery SystemsNeoplasmsNeoplastic Stem CellsStem Cell Niche

Identifiers

PMID20530700
PMCPMC3182451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.